Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up

Abstract

Figure 2 (a) Funduscopy 3 weeks after the injection of bevacizumab (4 mg). Size reduction of the yellowish mass. (b) OCT scan 3 weeks after the injection of bevacizumab (4 mg). Flattening of the serous retinal detachment. (c) B-mode ultrasonography 3 weeks after the injection of bevacizumab (4 mg). Choroidal mass with an extension of 6.4 Â 2.3 mm.

Intravitreal bevacizumab for choroidal metastases: the key to efficacy is simultaneous administration of systemic therapy

“…3 We would also tend to believe that CM from other solid tumors may also have variable degrees of responsiveness to IV-Bev, as has been documented in the literature, including those published in your journal. [4][5][6] In conclusion, while we fully agree with that use of IV-Bev for CM should not delay initiation of other treatment modalities, we strongly believe that this implies using the most appropriate form of systemic therapy in combination with IV-Bev rather than not using IV-Bev at all.…”

Intravitreal bevacizumab in the successful management of choroidal metastases secondary to lung and breast cancer unresponsive to systemic therapy: a case series

“…Choroidal metastases from lung cancer have been successfully treated with intravenous bevacizumab and chemotherapy 7 and intravitreal bevacizumab with concurrent chemotherapy. 8 There have only been four case reports in the literature where patients with lung 9 and breast [10][11][12] tumours, found to have new choroidal lesions despite systemic therapy, were successfully treated with intravitreal bevacizumab.…”

“…6 A few recent case reports have described the management of metastatic choroidal lesions through intravenous and/or intravitreal administration of bevacizumab with encouraging results. [7][8][9][10][11][12] We employed intravitreal bevacizumab in the management of three patients with primitive tumours of the lung and breast who developed choroidal metastases during chemotherapy. The study was approved by the Local Ethics Committee.…”

Failure of intravitreal bevacizumab in the treatment of choroidal metastasis

“…[2][3][4][5][6][7][8][9] Our outcomes in two cases of adenocarcinoma of caecum, one breast carcinoma, and one adenocarcinoma of lung do not replicate this finding. Difference in pathologies do not explain this, as good effects have been described treating metastases from the same primaries: colon, 4 breast, 2,5,8 and lung. 6 One case, a breast metastasis, who had undergone EBRT in the previous 4 months with no immediate response, did regress after intravitreal bevacizumab.…”

“…We used bevacizumab 1.25 mg in 0.05 ml, prepared from a vial commercially available for intravitreal use (Avastin). Previous reports have used bevacizumab 2.5 mg 3,5,6,9 and others 4 mg. 2,4 The most recent cohort published 7 used bevacizumab 1.25 mg and report regression in 3 cases with comparable pathologies.…”